Browsing Tag
biotech news
5 posts
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases
Candid Therapeutics begins Phase 1 trials of BCMA and CD20 T-cell engagers across five autoimmune diseases; institutional interest builds around TCE approach.
What is HARLIKU and how will Cycle’s FDA-approved AKU drug help patients starting July 2025?
Cycle Pharmaceuticals secures FDA approval for HARLIKU™, the first approved treatment for alkaptonuria (AKU); launch in the U.S. expected July 2025.